Blake Borgeson - 19 Mar 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
19 Mar 2024
Net transactions value
-$216,423
Form type
4
Filing time
21 Mar 2024, 17:38:02 UTC
Previous filing
07 Mar 2024
Next filing
03 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $216,423 -20,054 -0.28% $10.79 7,252,755 19 Mar 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.55 to $11.14 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.